Evidence map›Paper›PMID 41510883›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Identification and Characterization of an In Silico Designed Membrane-Active Peptide with Antiviral Properties.

Pascal von Maltitz, Niek van Hilten, Tatjana Weil, Thunchanok Thummaraj, Jeroen Methorst, Dennis Aschmann, Alexander Kros, Clarissa Read, Jasmina Gačanin, Herre Jelger Risselada and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pascal von MaltitzInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID https://orcid.org/0000-0003-0533-6999
Niek van HiltenDepartment of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, USA.ORCID https://orcid.org/0000-0003-1204-2489
Tatjana WeilInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID https://orcid.org/0000-0003-0925-2426
Thunchanok ThummarajMax Planck Institute for Polymer Research, Mainz, Germany.
Jeroen MethorstDepartment of Physics, Technical University Dortmund, Dortmund, Germany.ORCID https://orcid.org/0000-0003-4507-4882
Dennis AschmannLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.ORCID https://orcid.org/0009-0005-8889-0515
Alexander KrosLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-3983-3048
Clarissa ReadCentral Facility for Electron Microscopy, Ulm University, Ulm, Germany.ORCID https://orcid.org/0000-0002-4632-2684
Jasmina GačaninMax Planck Institute for Polymer Research, Mainz, Germany.ORCID https://orcid.org/0000-0002-8875-3757
Herre Jelger RisseladaDepartment of Physics, Technical University Dortmund, Dortmund, Germany.ORCID https://orcid.org/0000-0003-1410-6570
Jan MünchInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID https://orcid.org/0000-0001-7316-7141

Funding

Deutsche Forschungsgemeinschaft 530287567Deutsche Forschungsgemeinschaft CRC1279Federal Ministry of Research, Technology and Space (BMFTR; through a grant to J.G. in the consortium project "HEAL-X Bioink", subproject 13XP5207C)Max Planck Institute for Polymer ResearchThe Nando and Elsa Peretti Foundation through the Peretti-Schmucker Fellowship
6 · The paper itself

Abstract

Broad-spectrum antivirals are urgently needed to counter emerging viral threats. Targeting the viral envelope, an essential, conserved, and host-derived structure, offers a promising strategy with a low risk of resistance. Here, we report the in silico design and experimental characterization of P1.6, a 24-mer peptide generated using an evolutionary molecular dynamics (Evo-MD) platform and optimized to sense and exploit lipid packing defects in viral membranes. Among nine Evo-MD-derived candidates, P1.6 showed the strongest membrane-disruptive activity and inhibited HIV-1, Zika virus, and herpes simplex viruses with IC

Indexed as

Antiviral AgentsPeptidesViral EnvelopeComputer SimulationHIV-1HumansLiposomesMolecular Dynamics SimulationZika VirusAntiviral AgentsLiposomesPeptidesAMPantiviral peptidebroad‐spectrummembrane‐active

Identifiers

PMID41510883
PMCPMC13042762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.